Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is expected to continue its upward momentum due to its strong financial position, focus on increasing recurring revenue, and potential for long-term growth through product launches and international expansion. While potential risks exist, such as competition and potential disruptions from mergers, the company's attractive valuation and potential upside drivers make it a solid investment opportunity.

Bears say

Globus Medical is facing challenges from increasing competition in the robotic spine market and potential impact on revenue from the shift towards non-upfront models. While the company's earnings strength and margin improvement are currently driving growth, there are concerns about the sustainability of this trend in the future. Additionally, the company's controlled ownership structure and relatively low diversity on its Board and executive leadership team may raise corporate governance concerns. Overall, the negative outlook for Globus Medical is influenced by uncertainties in its revenue growth and operational efficiency, as well as potential risks regarding corporate governance.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.